Forte Biosciences, Inc.

NasdaqCM:FBRX Rapporto sulle azioni

Cap. di mercato: US$6.1m

Forte Biosciences Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Forte Biosciences.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili27.1%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento03 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:FBRX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026N/AN/AN/AN/A1
12/31/2025N/AN/AN/AN/A2
12/31/2024N/AN/AN/AN/A2
6/30/2024N/A-36-31-31N/A
3/31/2024N/A-32-30-30N/A
12/31/2023N/A-31-29-29N/A
9/30/2023N/A-30-23-23N/A
6/30/2023N/A-24-16-16N/A
3/31/2023N/A-18-11-11N/A
12/31/2022N/A-14-8-8N/A
9/30/2022N/A-12-9-9N/A
6/30/2022N/A-17-12-12N/A
3/31/2022N/A-19-15-15N/A
12/31/2021N/A-22-17-17N/A
9/30/2021N/A-23-17-17N/A
6/30/2021N/A-20-20-20N/A
3/31/2021N/A-49-20-20N/A
12/31/2020N/A-46-18-18N/A
9/30/2020N/A-43-15-15N/A
6/30/2020N/A-39-8-8N/A
3/31/2020N/A-5-5-5N/A
12/31/2019N/A-4-3-3N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if FBRX's forecast earnings growth is above the savings rate (2.5%).

Guadagni vs Mercato: Insufficient data to determine if FBRX's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if FBRX's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if FBRX's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: FBRX is forecast to have no revenue next year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if FBRX's Return on Equity is forecast to be high in 3 years time


Scoprire le aziende in crescita